However, germline and somatic BRCA2 mutations were significantly increased in all three categories: 3.25% and 6.29% of any-stage PCa, 4.51% and 10.26% of metastatic PCa, and 3.90% and 10.52% of metastatic CRPC patients, respectively [70]. Here, BRCA2 is linked to posterior cortical atrophy.